May 31st 2023
A study comparing the symptoms of female sexual arousal disorder in premenopausal and postmenopausal women has been published by Daré Bioscience.
Expert Illustrations & Commentaries™: Targeting Immune Cells to Treat Multiple Sclerosis
View More
Patient, Provider, & Caregiver Connection: Individualizing Care in Multiple Sclerosis – Understanding Patient Challenges and the Role of Innovative Treatment
View More
7th Annual New York Cardio-Endo-Renal Collaborative (NY CERC)
10/21/2023
View More
6th Annual Advanced Practice Collaborative
09/08/2023-09/09/2023
View More
22nd Annual International Congress on the Future of Breast Cancer® West
View More
4th Annual International Congress on the Future of Women’s Health™
07/22/2023
View More
22nd Annual International Congress on the Future of Breast Cancer® East
View More
Patient, Provider, and Caregiver Connection™: Incorporating the Patient Journey into HS Diagnosis and Management Practices
View More
Higher risk of autoimmune, other disorders associated with children of mothers with alopecia areata
New data indicates that increased risk for offspring in developing different disorders is associated with maternal alopecia areata exposure, expanding the available information on alopecia and maternal autoimmunity.
Spironolactone found to be effective alternative to oral antibiotics for women with acne
New data indicates the usefulness of spironolactone as an alternative to oral antibiotics for women in the UK with acne vulgaris, given increasing resistance to antibiotics due to widespread use.
Haywood Brown, MD, on the current landscape of maternal mortality in the United States
May 22nd 2023At the 2023 ACOG Annual Clinical and Scientific Meeting, Haywood Brown, MD, discusses the current maternal mortality rate in the United States, as well as disparities affecting different racial and ethnic groups.
'It's about time,' fezolinetant approval and latest research showcased at annual meeting
May 19th 2023Genevieve Neal-Perry, MD, PhD, talks about the recent approval of fezolinetant (Veozah; Astellas Pharma) and her latest phase 3 research presented at the 2023 ACOG Annual Clinical and Scientific Meeting.